P2RY12 and COVID-19: Ticagrelor, an orally administered selective reversible P2Y12 receptor antagonist, preventing P2Y12 and ADP mediated platelet activation and aggregation has been approved for prevention of severe cardiovascular events and may be suited for sepsis-induced coagulopathy in COVID-19 (230) especially since in silico analysis suggests ticagrelor also bound the main protease and spike proteins of SARS-CoV-2 (231).